Cailin Conner

Urban Health Today

A study in the World Allergy Organization Journal investigated the global prescription patterns of omalizumab among allergists and immunologists treating patients with chronic spontaneous urticaria (CSU).
Researchers conducted an anonymous questionnaire survey, targeting members of the World Allergy Organization globally. The survey aimed to gather insights into the demographics, clinical experience, and prescription practices of allergists and immunologists. The categorical data were subjected to analysis using SAS 9.4.
Out of 348 respondents, 82% reported prescribing omalizumab for patients with CSU. The average age of participants was 51 years (range, 28-90 years), and the gender distribution was 48% male and 52% female. A total of 58% possessed more than 15 years of clinical experience, while 10% had less than 5 years.
The highest utilization of omalizumab was observed among younger practitioners. Practitioners in private clinics (42%) and public hospitals (36%) accounted for the majority, followed by academia (24%), private hospitals (18%), and community practice (4%).
Cost (63%) and restricted formulary access (24%) emerged as the primary barriers to prescribing omalizumab. Safety considerations (63%) and concerns about adverse events (47%) were pivotal factors that influenced treatment decisions.
Approximately 22% of respondents reported that 80% to 100% of their patients with CSU exhibited a complete response to omalizumab. For partial or nonresponders, 34% preferred increasing the frequency (every 2 weeks), and 18% favored increasing the dose (600 mg every 4 weeks).
“Most clinicians favored omalizumab over other potential treatments due to safety. Although younger clinicians were more likely to prescribe omalizumab, cost and formulary access were major barriers,” the authors of the study wrote. “Only 22% of respondents reported 80% or greater of their patients had complete response to omalizumab, indicating the need for novel CSU therapies.”
Source: <a href="https://www.worldallergyorganizationjournal.org/article/S1939-4551(23)00118-7/fulltext" target="_blank" rel="noopener">World Allergy Organization Journal</a>

Tamara Thomas

Circadian Rhythm Disruptions Linked to Higher Alzheimer’s Amyloid Levels in Brain

Alzheimer's & Dementia

Losing a Loved One Heightens Physical Health Risks

Women's Health

How Social Media Could Be Fueling Overdiagnosis

Public Health

Latest News

Majority of Allergists Prescribe Omalizumab for CSU, Survey Finds

Chronic Spontaneous Urticaria

A global survey of allergists and immunologists revealed that 82% favored prescribing omalizumab for CSU due to perceived safety.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe